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Patient Selection for Ventricular Assist Devices
A Moving Target
Leslie W. Miller, MD, Maya Guglin, MD, PHD
Tampa, Florida
The number of patients with advanced heart failure that has become unresponsive to conventional medical
therapy is increasing rapidly. One of the most promising new alternatives to heart transplantation is use of
ventricular assist devices (VADs). To date, there are no guidelines for appropriate selection for use of these
devices that are approved by national societies in the field. This review addresses all of the general criteria
for clinicians to keep in mind regarding when to refer a patient for evaluation and the specific issues ad-
dressed in patient selection. The field of mechanical circulatory support has advanced significantly over the
past 10 years, resulting in rapid expansion of patients with advanced heart failure who can benefit from
implantable devices. With progress of technology, limitations associated with age, body size, and comor-
bidities gradually become less prohibitive. The continuing simplification of design along with continued re-
duction in size of the devices, plus eventual elimination of the external drive line will make the use of VADs
a superior option to heart transplant and even to medical management in many patients. We anticipate
that the patient selection process outlined in the present review will continue to shift toward less advanced
cases of heart failure. (J Am Coll Cardiol 2013;61:1209–21) © 2013 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1029No other field in cardiology is experiencing such explosive
growth as mechanical circulatory support for advanced heart
failure (HF). As increasing numbers of patients become
refractory to optimized medical therapy, the need for
definitive treatment modalities grow. Previously, the only
proven treatment for these patients was heart transplanta-
tion. While the number of transplants has reached a plateau
at 4,500 a year worldwide and 2,200 per year in the United
States, growth in the number of recipients of long-term
ventricular assist devices (VADs) is accelerating (Fig. 1).
Estimates of potential recipients for VAD support vary
widely, confounded by liberal use of definitions like “refrac-
tory HF,” “advanced HF,” and “stage D” HF, as well as
changing indications for implantation. In some communi-
ties, the prevalence may be as low as 0.2% of the general HF
population (1), while in others, it can be 3.1% of all adults
(2). We estimate that the number of potential recipients for
VAD support ranges from 150,000 to 250,000 (Fig. 2) (3).
There are published guidelines for patient selection for
heart transplantation that are endorsed by most societies in
the field, but there is much less guidance on selection of
patients for mechanical support (4). The American Heart
Association (AHA)/American College of Cardiology
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to the contents of this paper to disclose.Manuscript received April 6, 2012; revised manuscript received August 29, 2012;
accepted August 30, 2012.(ACC) guidelines for 2005, for example, recommended left
VAD (LVAD) implantation as “reasonable in highly se-
lected patients with refractory end-stage HF and an esti-
mated 1-year mortality over 50% with medical therapy” (5).
This text is unchanged in the 2009 update (6). There is one
recent “best practice” document that includes both patient
selection and clinical management of continuous flow
LVADs (7).
There has been very little improvement in survival with
medical treatment of advanced HF, with no new drugs
shown to improve survival for over 10 years. In addition, we
seem to be unable to alter disease progression once patients
are hospitalized, as HF remains the greatest cause of
readmission, with rates averaging over 20% at 1 month and
50% at 6 months. There are some tools to estimate survival
in these patients (e.g., the Seattle Heart Failure model [8]
and the Heart Failure Survival Score [9]), but none includes
the number of hospitalizations, which is one of the most
powerful predictors of survival (Fig. 3) (10). The previous
New York Heart Association (NYHA) classification is very
subjective and inconsistent, with large interobserver vari-
ability. This problem is further compounded by whether the
patient is classified at the time of a hospital admission,
typically as NYHA class IV, or 1 month after discharge,
when they are much less symptomatic and may be consid-
ered class III. Not surprisingly, therefore, estimates for
1-year mortality in patients judged to have class IV or stage D
HF range from 15% to 35%, as NYHA class IV or stage D
HF includes those patients dependent on an inotropic agent
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Patient Selection for VADs March 26, 2013:1209–21in the hospital, as well as those
who are symptom limited but are
at home on oral medications
(11). In contrast to the modest
absolute increases in survival
with medical therapy, even the
first generation of LVAD, the
pulsatile HeartMate I (Thoratec
Corporation, Pleasanton, Cali-
fornia), demonstrated the largest
absolute improvement in survival
(24% absolute and 100% relative
increase compared to medical
management) in an HF trial to
date.
Introduction of the second-
generation continuous flow LVAD,
HeartMate II (Thoratec Corpora-
tion), increased survival to 68% at 1
year in a clinical trial of patients as
a bridge to transplantation (12),
and as has been shown in all
published trials of LVADs to
date, survival improved signifi-
cantly to 85% in patients enrolled in the post-approval phase
of the trial (13) and even higher in a nontrial experience
with HeartMate II (14) (Fig. 4). Most recently, the AD-
ANCE (Action in Diabetes and Vascular Disease: Pre-
erax and Diamicron MR Controlled Evaluation) trial of a
hird-generation continuous flow device, the Heartware
HeartWare, Framingham, MA), has reported 92% survival
t 6 months in a clinical trial as a bridge to transplantation
Fig. 5). Importantly, the control arm in that study was from
he INTERMACS (Interagency Registry for Mechanically
ssisted Circulatory Support), which showed nearly iden-
ical excellent survival in centers not involved in a prospec-
ive trial.
The very significant improvement in survival with the
ewer LVADs noted above is in large part because of the
normous improvement in device durability, with similar
uccess now demonstrated with nearly all new continuous
ow LVADs, which have only a single moving part and
ikely 10-year freedom from mechanical failure. This obser-
ation has re-emphasized that patient selection and timing
f device implantation are the major determinants of success
n the field of mechanical support for advanced HF.
Currently, VADs seem to be significantly underuti-
ized. In a mere 10 years, design of the devices, implan-
ation techniques, follow-up routines (15), and prognoses
ave changed dramatically. As they continue to change
apidly, so do the selection criteria for patients who can
ain years of a quality life from mechanical circulatory
upport. Rapid growth in this field has exceeded the
ealization of these outcomes by many practicing clini-
ians. This report review the specific criteria to be used to
Abbreviations
and Acronyms
ALT  alanine
aminotransferase
AST  aspartate
aminotransferase
BUN  blood urea nitrogen
CVA  cerebrovascular
accident
CVP  central venous
pressure
HCT  hematocrit
OR  odds ratio
PAP  pulmonary arterial
pressure
PCWP  pulmonary
capillary wedge pressure
RAP  right atrial pressure
SVI  stroke volume index
TPG  transpulmonary
gradient
WU  Wood unit(s)ecide when to consider referring a patient for LVADherapy, with particular attention to those factors with
he greatest impact on survival to hospital discharge and
ong term, as well as discussion of the controversy of age
imit and severity of HF.
ndications for Mechanical Circulatory Support
here are three major often overlapping indications for the
se of VADs: 1) as a bridge to transplantation for heart
ransplant candidates who are either “too sick” to wait for a
onor to be identified because of severe acute, or acute-on-
hronic HF, or have contraindications to transplantation,
hich are deemed to be transient; 2) as a lifelong support
lternative for patients deemed ineligible for a heart trans-
lantation, so-called destination therapy; and 3) as a bridge
o myocardial recovery. A fourth term, bridge-to-a-bridge,
s used for those patients who present with severe shock or
ollowing cardiac arrest and are supported with a temporary
upport VAD to see if they become candidates for a
ong-term support device.
Interestingly, the most common indication listed for
0% of all patients entered in the INTERMACS is
ridge to decision. It is used when the best long-term
ption for a given patient is unclear at the time of LVAD
mplantation. For example, some patients for whom the
nitial intent was destination therapy may recover renal
nd hepatic function or have documented significant
ecrease in pulmonary hypertension and then become
ransplant candidates. Conversely, some patients who
ere originally listed as transplant candidates may be so
atisfied with their quality of life on mechanical circula-
ory support that they elect to remain on the LVAD
ather than undergo transplantation.
In part because of changes in the prioritization of trans-
lant candidates to primarily status 1A, or the very sickest
atients, an increasing number of patients are receiving
Figure 1 Dynamics of the Heart Transplant and LVAD
Implant Numbers in the United States 2006 to 2010
While the number of transplants remains almost constant, there is accelerating
growth in LVADs. Numbers for the graph are from INTERMACS and U.S. Depart-
ment of Health and Human Services, respectively. Because INTERMACS statis-
tics started in June 2006, we doubled the number of VADs for 2006.
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March 26, 2013:1209–21 Patient Selection for VADsLVAD therapy at the time of transplantation because of
either deterioration while on the transplant waiting list or
are in refractory HF when first evaluated (3,10,16–18).
Data from the ISHLT (International Society for Heart and
Lung Transplantation) registry show that more than 33% of
all patients undergo transplantation with an LVAD in place
(17,18). This percentage varies greatly across the country to
as high as 75% in programs where donor availability is low.
Outcomes after transplantation are not different in those
who were “bridged” with an LVAD compared with those
who were not, and duration of mechanical support does not
seem to have an adverse impact on mortality after cardiac
transplantation (19). Most of the patients bridged with an
LVAD are, in fact, the more ideal candidates, as they are
functionally much better and, in general, have better organ
Figure 2 Current Estimate of the Number of Advanced HF Patie
This represents approximate number of potential VAD candidates. Data from Mille
Figure 3 Median Survival Decreases Progressively After Each H
Hospital admissions not only decrease quality of life, but they are also associatedfunction and pulmonary artery pressure at the time of
transplantation.
Given the progress achieved in VAD outcomes demon-
strated in controlled clinical trials, it seems obsolete to make
the preimplant determination of whether VAD for a given
patient is as bridge to transplant, recovery, or destination
and is much more prudent to establish that a patient is in
need of mechanical circulatory support, regardless of age or
overall comorbidities, and leave the question to be resolved
by both the patient and the clinicians at a later point in time
of support. We anticipate that the future direction is to
abandon rigid categories before the implantation and to
make the decision on mechanical circulatory support based
on: 1) presence of indications; and 2) absence of contrain-
dications.
F  heart failure.
talization for HF
horter longevity. Data from Stehlik et al. (10). HF  heart failure.nts
r (3). Hospi
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p
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Patient Selection for VADs March 26, 2013:1209–21General Criteria for Patient Selection for
Mechanical Circulatory Support
Indications for mechanical circulatory support are generally
derived from inclusion criteria of clinical trials (Table 1). It
is indicated for patients who have symptomatic advanced
HF refractory to conventional therapy, including those who
become inotrope dependent with significantly impaired
cardiac function, with left ventricular ejection fraction typ-
Figure 4 Post-Trial Versus Trial Survival With Continuous Flow
In this case, real life appears to be better than the trial. Data from John et al. (14
Figure 5 Survival With Heartware Intrapericardial Device
Results from the ADVANCE trial (82).ically below 25%. In ambulatory patients, functional status is
severely compromised by HF. The most widely used criteria
for proving a cardiac cause of HF and candidacy for
mechanical circulatory support or transplantation is peak
oxygen consumption (VO2) of 14 ml/kg/min or 50%
redicted for age, sex, and body surface area on cardiopul-
onary stress test results. Although there are no specific
emodynamic criteria for device implantation, a cardiac
D  left ventricular assist device.LVAD
). LVA
c
h
f
m
f
d
p
m
f
t
w
I
c
w
i
r
t
P
o
(
P
a
a
r
p
f
l
c
s
b
c
t
n
S
m
c
t
p
H
f
a
e
f
p
c
c
e
a
f
t
w
c
l
y
s
m
a
m
t
h
h
f
m
t
ociation
1213JACC Vol. 61, No. 12, 2013 Miller and Guglin
March 26, 2013:1209–21 Patient Selection for VADsindex 2 l/min/m2 despite inotropic agents should prompt
onsideration of mechanical pump placement. Worsening
emodynamics or increasing inotropic requirements or need
or use of vasopressors to maintain systemic blood pressure
ay be more important than the absolute numbers, and
ollowing strict hemodynamic criteria should not delay the
ecision to use VADs. There are several categories of
atients developing such profound hemodynamic compro-
ise. Most of the information about them has been derived
rom the INTERMACS (20).
In 2009, 80% of patients received LVAD as bridge to
ransplant, 15% as destination therapy, and 5% recovered
ith subsequent VAD explantation. According to the
NTERMACS classification (Table 2), despite published
ase series and results of risk score stratification showing the
orst outcomes in the sickest patients, 80% of patients were
n the two most critical levels 1 and 2, with 42% and 38%,
espectively. Only 8% of patients were stable on inotropic
herapy, and only 12% were free of inotropic support (21).
atients with a profile of 1 or 2 have been shown to have not
nly inferior survival but also much greater lengths of stay
42 vs. 16 days) than patients who are less acutely sick (22).
atients with cardiogenic shock such as postcardiotomy,
cute myocardial infarction, acute myocarditis, or cardiac
rrest (INTERMACS level 1 “crash and burn”) who cur-
ently have the highest mortality (over 60% even with
ercutaneous or surgical revascularization) (23), may benefit
rom short-term circulatory support rather than from
ong-term LVAD. Several types of short-term devices are
Criteria for Inclusion Into Destination Therapy CTable 1 Criteria for Inclusion Into Destinatio
Trial REMATCH,
Clinical scenario 1. NYHA class IV for
despite best med
2. Inotrope depende
LVEF 25%
Peak oxygen consumption 12 ml/kg/min
LVEF  left ventricular ejection fraction; NYHA  New York Heart Ass
INTERMACS Patient Profiles (20)Table 2 INTERMACS Patient Profiles (20)
Level Definition Description
1 Critical cardiogenic shock “Crash and burn”
2 Progressive decline “Sliding fast”
3 Stable but inotrope dependent Stable but dependent
4 Recurrent advanced HF “Frequent flyer”
5 Exertion intolerant “Housebound”
6 Exertion limited “Walking wounded”
7 Advanced NYHA class III Advanced NYHA class IIIFHF  heart failure; NYHA  New York Heart Association.urrently available (24–26). Fortunately, there has been
ome reduction in the severity of HF and overall comor-
idities of patients now being selected for mechanical
irculatory support, as confirmed in recent reports from
he INTERMACS, particularly for indication for desti-
ation therapy (17).
pecific criteria for candidate selection for long-term
echanical support. It is generally agreed that patients
onsidered for long-term circulatory support should fulfill
he clinical, functional, and hemodynamic criteria for trans-
lant recipient selection. Patients with advanced systolic
F, severely reduced left ventricular systolic function,
unctional limitations caused by HF, and frequent hospital
dmissions related to HF are appropriate candidates. How-
ver, the indications can be expanded, as reflected in the
ollowing sections. Many limitations that would preclude a
otential transplant recipient from getting the donor organ
an be lifted because no donor heart is needed. Unlike the
ase of heart transplantation, when the physician must apply
thical considerations and answer the question of the
ppropriateness of the organ allocation, the decision process
or VAD implantation is more medical and social. Addi-
ionally, the severity of pulmonary hypertension, which
ould be prohibitive for cardiac transplantation, is not a
ontraindication for the VAD.
Absolute contraindications include systemic illness with a
ife expectancy of less than 2 years or malignancy within 5
ears, irreversible renal or hepatic dysfunction, severe ob-
tructive pulmonary disease, or other systemic disease with
ultiorgan involvement (27). However, LVAD may be an
cceptable option for a patient with recent cancer, which
ight theoretically be cured but who is unable to survive
he 5-year disease-free interval typically required for
eart transplantation. Similarly, active infection with
uman immunodeficiency virus or advanced end-organ
unction such as a serum creatinine concentration of 3.0
g/dl may not preclude patients from LVAD implanta-
ion (28). The overall evaluation process is summarized in
l Trialserapy Clinical Trials
11) HeartMate II, 2009 (12)
st 90 days
erapy or
1. NYHA class IIIB or IV for at
least 45 days despite best
medical therapy or for the
60 days before enrollment or
2. Intra-aortic balloon pump for
7 days or
3. Inotrope dependence for at
least 14 days before
enrollment.
25%
14 ml/kg/min or
50% predicted
.linican Th
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Over time, a large number of variables have been identified,
largely by univariate analysis, to be associated with increased
mortality in patients with HF. However, no one variable can
be used to select candidates for mechanical circulatory
support. As mechanical pumps become more and more
acceptable for less sick HF patients, it is important to
consider not only hemodynamic instability but also other
features of HF, which limit longevity and compromise
quality of life. Several composite risk scores have been
developed, which can help stratify patients and predict
survival for outpatients, such as the Seattle Heart Failure
Risk Score and the Heart Failure Survival Score mentioned
earlier. Both score systems have limitations but have been
shown to give fairly reasonable estimates of 1-year survival.
The Seattle Heart Failure Model, although developed with
less sick HF patients, appears to be working better than
other scores for mortality prediction before and after VAD
implantation (29). Some authors advocate using this score as
a virtual control group, predicting the “would be” out-
comes if patients were treated medically. The model was
also able to predict shorter duration of hospital stay and
more favorable hospital course in LVAD recipients (30).
The Seattle Heart Failure Model has been selected for
use in the REVIVE-IT (Randomized Evaluation of
VAD InterVEntion before Inotropic Therapy) trial, and
one of the stated goals of that study was to improve risk
stratification by adding variables not included in these
two models, such as the number of hospitalization for HF
and renal function.
More recently, a risk score has been developed to assess
Figure 6 Algorithm for Selection of LVAD Candidatesperioperative risk of dying prior to hospital discharge after oLVAD implantation. This Lietz-Miller score was devel-
oped from a large registry of destination therapy patients
who received implants of a pulsatile device after U.S. Food
and Drug Administration (FDA) approval for commercial
use. Use of this score was able to identify those who are at
a relatively low risk versus those with a prohibitive risk of
dying based on standard laboratory and clinical variables.
The major new observations from that study were to
point out the importance of nutritional status before a
major surgical procedure in patients with advanced HF
and the added risk of patients with platelet counts below
148,000 or internation normalized ratio 1.2. The score
was validated with a small follow-up study but did not
perform as well in a series of over 600 patients who
underwent use of continuous flow pumps as bridge to
transplantation (31).
Pulmonary Hypertension
From a hemodynamic standpoint, the most serious contra-
indication for cardiac transplantation is severe fixed pulmo-
nary hypertension, defined as pulmonary artery systolic
pressure 60 mm Hg, mean transpulmonary gradient 15
m Hg, or pulmonary vascular resistance 6 Wood units,
hich are unresponsive to treatment with various agents
lone or in combination. These criteria are correlated with a
ery high risk for transplantation because of the high
ikelihood of right ventricular (RV) failure after surgery,
hich is the second leading cause of death in the first month
fter transplant. However, pulmonary hypertension is not a
ontraindication to LVAD placement unless there is severe
V failure pre-LVAD, especially if caused by nonischemic
r idiopathic cardiomyopathy. It appears that LVAD place-
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March 26, 2013:1209–21 Patient Selection for VADsment represents the best tool for reversal of “fixed” or
unresponsive pulmonary hypertension. The complete LV
unloading achieved by LVAD support cannot be matched
by any medical therapy, and often pulmonary pressure and
pulmonary vascular resistance normalize after a variable
period of time, often as short as 2 to 3 months. The process
may be facilitated by use of sildenafil (32).
Right Ventricular Failure
RV failure after LVAD is associated with higher mortality,
greater risk of bleeding and/or reoperation, longer hospital-
izations, and a higher rate of renal insufficiency (33–35). As
noted above, absolute pulmonary pressure or resistance are
not important criteria for selection of a patient for an
LVAD, but the presence of RV failure pre-LVAD as
defined by right atrial pressure of other sophisticated mea-
surements such as tricuspid annular plane systolic excursion
(TAPSE) or RV stroke work index. Most patients in
cardiogenic shock or advanced HF refractory to medical
therapy evaluated for mechanical circulatory support can
be managed with only left ventricular support, LVAD.
However, the risk of RV failure after LVAD occurs in up
to 20% of patients, especially those with nonischemic
causes where both ventricles are often equally impaired.
In some cases, biventricular support is indicated. In
general, LV unloading is beneficial for RV (36). How-
ever, in the early postimplantation period, acute increase
in venous return and changing LV geometry can compro-
mise the RV. The rate of post-LVAD RV failure decreased
compared with early experience but is still substantial at 5%
to 13% (34,35).
It is remarkable that unlike in heart transplantation,
pulmonary hypertension and high pulmonary vascular resis-
tance do not predict post-LVAD RV failure. To the
contrary, lower pulmonary arterial pressure, reflecting poor
RV contractility, is a documented risk factor.
Multiple attempts have been made to predict RV failure
before LVAD implantation in order to plan biventricular
support when needed. Several studies identified multiple
risk factors for postimplantation RV failure (33,37–44), and
more than half of the risk factors are related to RV
dysfunction, such as renal and hepatic insufficiency second-
ary to congestion, elevated pressure in the right atrium
decreased RV stroke work index, and decreased RV con-
tractility by echocardiography (Table 3).
In a small group of patients, Deswarte et al. (45) reported
that an increase in TAPSE by 40% and/or an increase in
pulmonary artery systolic pressure over 30% with low-dose
dobutamine infusion ruled out post-LVAD RV failure with
100% specificity and sensitivity. It appears, therefore, that
the clinical syndrome of RV dysfunction before the implant
is the most powerful predictor of RV failure after LVAD
implantation. tRenal and Hepatic Dysfunction
Many patients with advanced HF have mild to moderate
abnormalities of renal function. The serum creatinine con-
centration may often exceed 2 mg/dl and creatinine clear-
ance below 50 ml/min, which both have been shown to
adversely impact survival after transplantation (46). While
renal dysfunction related to systemic congestion or impaired
renal perfusion secondary to HF may improve with diuresis
or inotropic agents, underlying intrinsic renal disease may
represent significant comorbidity. If cardiac insufficiency is
the primary cause of renal dysfunction it improves after the
LVAD implant or transplant (47,48). In patients with
baseline glomerular filtration rate of 41.7  11.5 ml/min, it
ncreased to 62.7  25.0 ml/min after 6 months of LVAD
upport (49).
If intrinsic renal disease is suspected, patients should
ndergo further workup with 24-h urine collection for
rotein excretion and creatinine clearance, renal ultrasonog-
aphy for kidney size, and possibly evaluation of the reno-
ascular system. Standard urinalysis will exclude most pa-
enchymal diseases. Although some centers consider severe
enal impairment with glomerular filtration rate 30 ml/
in a relative contraindication to LVAD, this approach
ay be too conservative and result in exclusion of many
andidates with high potential to recover. Being on chronic
emodialysis remains a contraindication for long-term
ADs as there are few if any dialysis centers that accept
atients with an LVAD. Besides, risk of infection is already
ncreased in LVAD patients, and the necessity to establish
nd maintain dialysis access further increases the danger.
eritoneal dialysis might be safer (50); however most
rograms will not consider implanting a long-term pump
nto a patient whose renal function is so profoundly com-
romised that chronic dialysis is needed.
Transaminase levels more than twice their normal value
ith or without elevated bilirubin, and associated coagula-
ion abnormalities may reflect right HF or passive conges-
ion; however, primary liver disease, in particular cirrhosis,
eeds to be excluded, which sometimes requires a liver
iopsy.
leeding risk. Bleeding has been one of the most common
omplications since the introduction of LVAD therapy,
ith a 4-fold increased risk of reoperation for bleeding over
tandard open heart surgery (51). This is caused by multiple
actors including abnormal coagulation at time of surgery,
ften because of preoperative use of warfarin and/or anti-
latelet agents or hepatic congestion, poor nutrition, high
enous pressures, and adhesions frequently occurring in
atients with previous sternotomy. There is now an impor-
ant second phase of the risk of bleeding that develops
eginning 1 month after implant, which may occur in up to
5% of patients. Increasing age seems to be most correlated
ith increased risk of bleeding. The most common site of
leeding is in the upper gastrointestinal tract (52–54) and is
ypically caused by or associated with development of
1216 Miller and Guglin JACC Vol. 61, No. 12, 2013
Patient Selection for VADs March 26, 2013:1209–21Risk Factors for RV Failure After LVAD ImplantationTable 3 Risk Factors for RV Failure After LVAD Implantation
Fisrt Author, Year (Ref. #) n
No. of RV
Failures (%)
Risk Factors for Post-VAD RV Failure
Factors Related to
Pre-Operative RV Dysfunction
Factors Unrelated to
Pre-Operative RV Dysfunction
Pulsatile LVADs
Kormos et al., 1996 (78) 40 17 (42.5) 1. Greater need for inotropic agents 1. Lower mixed venous oxygen saturation
Novacor 2. Lower RVEF/inotropic need ratio 2. Pulmonary edema
3. None of the patients with RVEF 20%
developed RV failure
3. Poor mental status
4. Fever without infection
4. Higher creatinine
Fukamachi et al., 1999 (38)
HeartMate I
100 1. Lower pre-operative mean pulmonary arterial
pressure
2. Lower RV stroke work index
3. Elevated aspartate aminotransferase
1. Younger age
2. Female
3. Smaller patients
4. Myocarditis
Kavarana et al. 2002 (39) 69 21 (30.4) 1. Higher bilirubin 1. Intra-operative bleeding
HeartMate I 2. Trend toward lower preoperative RV stroke
work index
Ochiai et al., 2002 (40) 245 1. Non-ischemic cause 1. Female
189 HeartMate I (77%) and 56
Novacor (23%)
2. Preoperative circulatory support
3. Low mean and diastolic pulmonary arterial
pressure
4. Low RV stroke work
5. Low RV stroke work index
2. Small body surface area
Dang et al., 2006 (33) 108 42 (38.9) 1. Elevated intra-operative central venous
pressure
1. Female
HeartMate I 2. Intra-operative lower systolic and mean blood
pressure
3. Lower intra-operative pulmonary arterial
pressure
Santambrogio, et al., 2006 (44)
Novacor
48 8 (16) 1. Higher aspartate aminotransferase
2. Higher alanine aminotransferase. Higher blood
urea nitrogen
3. Higher blood urea nitrogen
4. Higher creatinine
5. Lower pulmonary arterial pressure
1. Pre-operative mechanical ventilation
Pulsatile and continuous flow
LVADs
Matthews et al., 2008 (42) 197 68 (35) 1. Vasopressor requirement (OR: 4.8) 1. Cardiac arrest preoperatively (OR: 2)
Mixed devices 2. Aspartate aminotransferase 80 IU/l
(OR: 3.2)
3. Bilirubin 2.0 mg/dl
4. Creatinine 2.3 mg/dl (OR: 5.56)
5. Need for hemodialysis (OR: 9.9)
6. Severe RV systolic dysfunction (OR: 2.2)
7. Blood urea nitrogen 48 mg/dl (OR: 2.1)
8. Bilirubin 2.0 mg/dl (OR: 3.6)
9. Pulmonary artery systolic pressure
50 mm Hg
10. RV stroke work index 450 mm Hg  ml/m2
(OR: 2.3)
11. Severe tricuspid regurgitation (OR: 1.3)
2. Smaller body surface area
3. History of cerebrovascular accident
4. Need for ventilatory support (OR: 3.2)
5. Temporary mechanical LV bridge
before LVAD (OR: 3)
6. Absence of a prior sternotomy
7. Intravenous anti-arrhythmic agents
(OR: 2.6)
8. White blood cells 12.2 k/mm3
(OR: 2.71)
9. Platelet count  120 k/mm3
(OR: 3.4)
10. Albumin  3.0 g/dl (OR: 1.9)
Fitzpatrick et al., 2008 (79)
Mixed devices
266 1. Severe RV dysfunction. (OR: 5.0)
2. Low RV stroke work index
RV stroke work index 0.25 mm Hg  l/m2
(OR: 5.1)
3. Higher central venous pressure
4. Lower pulmonary arterial pressure
5. Creatinine 1.9 mg/dl (OR: 4.8)
1. Mechanical ventilation
2. Previous cardiac surgery (OR: 4.5)
3. Cardiac index 2.2 l/min/m2
(OR: 5.7)
4. Intra-aortic balloon pump
5. Pre-operative circulatory support
6. Female
7. Smaller body surface area
8. Systolic blood pressure 96 mm Hg
(OR: 2.9)
9. Lower mixed venous saturationContinued on the next page
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March 26, 2013:1209–21 Patient Selection for VADsarterial-venous malformations, primarily located in the
stomach or early portions of the small bowel. This seems to
be a unique sequela of continuous flow physiology, as it was
not seen with the first generation of pulsatile flow devices.
Patients with prior history of gastrointestinal bleeding
should have upper and lower endoscopy before LVAD.
Recent attention has been directed at the uniform reduction
in multimers of von Willebrand factor in the serum in
response to nonpulsatile flow as one possible explanation for
the increased bleeding associated with continuous flow
VADs (55,56). Presence of bleeding diathesis may be a
serious contraindication to LVAD unless coagulopathy is
caused by reversible hepatic dysfunction. Low platelet count
before implantation also predicts poor outcomes. Some-
times, presence of heparin-induced thrombocytopenia anti-
body needs to be excluded.
Patient Size Considerations
Implantation of LVADs was previously restricted to pa-
tients with a body surface area 1.5 m2, but the continuous
ow LVADs, which are one-seventh the size of pulsatile
evices, have been shown to be safely used in patients as low
s 1.3 m2 (12), which has allowed these nonpulsatile VADS
to be used in a significantly higher percentage of women
and smaller adults and adolescents. The Heartware
LVAD, which is implanted intrapericardially, practically
does not have body size limitations. This is in contrast to
heart transplantation where most programs limit donors
to  15% of the weight of the recipient.
There are many groups that have been underserved by
LVAD therapy including women, due primarily to the large
ContinuedTable 3 Continued
First Author, Year (Ref. #) n
No. of RV
Failures (%) Pr
Dracos et al., 2010 (37)
Mixed Thoratec and
Novacor devices
175 1. Higher b
2. Higher r
Continuous flow LVADs
Kormos et al., 2010 (80)
HeartMate II
484 65 (13) 1.Central ve
2. Central ve
wedge pr
3. RV stroke
4. Blood ure
5. Aspartate
(OR: 1.7)
Baumwol et al.,
2011 (81)
Heartware
40 13 (32.5) 1. More seve
LVAD  left ventricular assist device; OR  odds ratio; RV  right ventricle; VAD  ventricular assize of the first-generation pulsatile LVADs. The percent- iage of women in recent LVAD trials of the much smaller
continuous flow pumps has increased from 8% to 25%, with
comparable results to males.
Obesity. There are conflicting data about the influence of
obesity on transplant outcomes. Obesity may be associated
with increased morbidity, complications such as infection,
and poor perioperative survival and difficulty identifying an
appropriately sized donor heart. The 5-year mortality can
double in obese patients compared with normal-weight
patients (57,58). In many centers, body mass index 35
kg/m2 is a relative contraindication for cardiac transplan-
ation. Such patients are encouraged to lose weight before
isting. On the other hand, the same degree of obesity
ay not be a contraindication to LVAD implantation.
ne-year survival of morbidly obese HF patients who
eceive LVAD as destination treatment was not different
rom patients with normal weight (59). In a recent report,
lthough infections occur more frequently in the over-
eight, primarily because of drivelines, which rest within
kin folds (60). In some cases, patients with LVAD
anage to lose so much weight that they became accept-
ble candidates and were successfully transplanted (61).
here is increasing interest in before or after LVAD
ariatric surgery to improve weight loss and reduce
otential complications. Overall, it appears that at least
id-term outcomes are comparable across the whole
pectrum of body mass index (62).
achexia. The patient with cardiac cachexia marked by
oor nutrition status and low albumin and total protein
oncentrations (3.5 mg/dl and 6 mg/dl, respectively) is at
high risk for postoperative death as well as complications,
Risk Factors for Post-VAD RV Failure
ctors Related to
rative RV Dysfunction
Factors Unrelated to
Pre-Operative RV Dysfunction
rial pressure
1. Pre-operative intra-aortic balloon
counterpulsation (OR: 3.9)
2. Pre-operative intubation
3. Lower platelets
4. Lower cholesterol
5. Smaller left ventricular size
6. Increased pulmonary vascular
resistance: 2. 8–4.2 Wood units
(OR: 3.0) 4.3 Wood units (OR: 4.1)
7. Destination therapy (OR: 3.3)
ressure 15 mm Hg (OR: 2.1)
pressure/pulmonary capillary
0.63 (OR: 2.5)
index 300 (OR: 2.9)
gen 39 mg/dl (OR: 1.7)
transferase 49 mg/dl
1. Ventilatory support (OR: 5.7)
2. Hematocrit  31% OR (2.3)
3. More blood transfusions
4. White blood cells 10.4  103/ml
(OR: 2.2)
uspid regurgitation
ice.Fa
e-Ope
ilirubin
ight at
nous p
nous
essure
work
a nitro
amino
re tricnfection, and poor wound healing. Prealbumin and total
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status and should be evaluated in all candidates for LVAD
therapy. Nutritional issues have to be addressed before the
implant to optimize outcomes (63).
Age. One of the most controversial issues in the field of
patient selection for advanced HF is age. Many transplant
programs are reluctant to list “elderly” candidates. The
cutoff age varies but is typically between 65 and 71 years of
age. In contrast, there is no absolute age cutoff for LVADs,
and older patients may have easier access to mechanical
pumps than to donor organs. While some authors are
relatively pessimistic, reporting low 1-year survival in
patients over 65 years of age (64), others report excellent
outcomes. In a study of 30 patients over 70 years of age,
Adamson et al. (65) demonstrated survival and length of
stay that were no different from that in younger patients,
with good functional recovery and quality of life. Thus,
age should no longer be considered a limitation to LVAD
therapy, but older patients should be more closely eval-
uated for potential age-related diseases, such as malig-
nancy. Some geriatric scores like fragility indices (66)
might be helpful for additional stratification of elderly
candidates.
Psychosocial evaluation. Like current recommendations
for transplantation, all VAD candidates should undergo
evaluation by a trained mental health professional and social
workers in order to ensure that they are able to receive
adequate postoperative care and medications before the
decision is made to proceed with the surgery. Psychosocial
criteria that may predict a poor postoperative outcome
include previous noncompliance, chemical dependencies
(alcohol and drugs), lack of an adequate support system,
personality disorder, underlying mental illness, organic
brain disorders, or mental retardation. Intellectual func-
tion is a difficult assessment in these patients, who often
have very reduced cardiac output pre-LVAD and may
demonstrate improved cognitive function post-LVAD.
Most programs include some type of intellectual testing
before accepting a patient for LVAD placement to
minimize the risk of catastrophic problems such as
removing both batteries at one time or not recognizing
alarms on the device controller.
Structural Cardiac Diseases
Severe aortic regurgitation needs to be corrected simultane-
ously with LVAD placement to avoid a “closed loop”
circulation between LV and ascending aorta. In most cases,
a bioprosthetic valve is placed; sometimes aortic valve is
completely closed surgically, which makes the patient very
sensitive to any LVAD malfunction because they become
totally dependent on the mechanical pump (67). Mitral
valve surgery is necessary only in the presence of significant
mitral stenosis compromising LV filling. Intracardiac shunts
are typically closed at the time of VAD implantation.
Pre-existing mechanical or biological prosthetic valves, mi-tral or aortic, usually do not cause complications during
LVAD implantation (68,69). It may be worth mentioning
that in case of aortic valve insufficiency already in the
presence of LVAD, transcatheter aortic valve replacement is
a possibility (70). The growing population of adult patients
with congenital heart disease with RV failure is another pool
of potential candidates for VADs (71).
Infection
Active infection is a contraindication to VADs. Patients
with such infection should be aggressively treated in collab-
oration with infectious diseases specialists. Bacterial infec-
tions are especially dangerous because if the VAD is seeded,
it is almost impossible to sterilize with antibiotics. On the
other hand, controlled viral infections such as human
immunodeficiency virus infection may not be a contraindi-
cation to VADs (72).
Moving to Patients With
Less Severe Heart Failure
There is now a clear and rapidly escalating trend nationally
for patients to undergo LVAD implantation as a totally
elective operation, with an increasing percentage being
admitted from home for a scheduled surgery. This
approach has multiple advantages including reduced nos-
ocomial infection, generally better condition of the pa-
tient, having been at home rather than in an intensive
care unit for rest and nutrition, and overall functional
capacity. Boyle et al. (22) demonstrated that patients
with a less severe INTERMACS grade of HF at the time
of LVAD implantation have not only better survival but
also significantly shorter hospital lengths of stay than
those with more severe HF or shock at the time of
implantation. Most importantly, there is a clear trend to
offer mechanical circulatory support to less-severe HF
patients.
Until recently, mechanical circulatory support was
reserved for patients with profound shock and refractory
HF. However, the number of implantations is rapidly
growing. The very good outcomes now reported in
several clinical trials with continuous flow LVADs in
nonshock patients (7,12,73,74) has led to equipoise about
the presumed equality of outcomes with the use LVADs
versus standard medical therapy as a therapeutic option
for patients with less severe HF. Following recommen-
dations of an expert panel, the National Heart, Lung, and
Blood Institute has initiated the Randomized Evaluation
of VAD InterVEntion before Inotropic Therapy study,
which is a randomized trial comparing LVAD to optimal
medical therapy. This trial will hopefully more clearly
define the risk factors association with mortality in
today’s management of HF. The expected survival in the
LVAD cohort is predicted to be 75% to 80% at 1 year and
70% at 2 years. If this trial proves that LVAD therapy can
provide not only superior survival, but also significantly
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lead to the largest increase in LVAD therapy ever. The
MEDAMACS (Medical Arm of Mechanically Assisted
Circulatory Support) pilot screening trial will also shed
some light on the outcomes in patients with advanced HF
and help identify the next group of candidates who will
likely benefit from earlier VAD implantation.
Impact of New Devices
Development of new devices can once again change
dramatically the whole process of patient selection, shift-
ing it toward more stable and benign and less advanced
stages of the disease. Additionally, smaller and simpler
devices may reduce surgical complications and lower the
threshold for referral of patients for VADs. Recent
recommendation of the FDA advisory panel to approve
centrifugal HeartWare has paved the road to its approval
for commercial use in the near future. Smaller size and
intrapericardial location may help adoption of this pump,
provided that clinical outcomes are not inferior to the
currently used HeartMate II.
Another model being tested is a miniaturized LVAD
requiring only minimal surgery, which will potentially
expand indications to earlier stages of HF and increase the
market of candidates. It is implanted through the left
ventricular apex with a distal cannula in the ascending aorta.
This LVAD does not require sternotomy, device pocket,
cardiopulmonary bypass, ventricular coring, and construc-
tion of an outflow graft anastomosis (75).
Another concept that can potentially revolutionize the
approach to VAD candidate selection is partial circulation
support. The Synergy Pocket micro-pump device (Circu-
Lite, Inc., Saddle Brook, New Jersey) has the inflow cannula
in the left atrium and the outflow in the right subclavian
artery. It provides blood flow of 3 l/min. It has already
demonstrated significant and steady improvement of many
hemodynamic parameters (76,77). This device is implanted
off pump via a mini-thoracotomy and placed like a pace-
maker in a right subclavicular subcutaneous pocket (like a
pacemaker).
However, the real change in selection of a patient for
LVAD or heart transplant will occur when eventually the
problem of transcutaneous energy supply is solved and the “Achil-
les heel” of all currently available devices, namely the driveline
going through the skin and posing continuous risk for
infection, disappears.
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